Drug manufacturers agree for halve prices for safe access to China

Photographer: Mikael Sjoberg / Bloomberg

Drug users AstraZeneca PLC and GlaxoSmithKline plc two BeiGene Ltd. Has agreed to cut the prices of some of its new drugs in China by an average of 51% to be covered by the country’s National Insurance Fund.

A total of 119 new therapies – treatment of pulmonary diseases and diseases ranging from diabetes to cancer and lupus – after coverage for coverage by state-run medical safety net, national Healthcare The Security Administration stated in a notice that it was posted Website monday.

10 percentage points less than the average price cut Last year, both domestic and foreign pharmaceutical companies are relieved that their profits have been erased by Beijing’s push to reduce health care costs. Companies are also eager to get their treatment at a discount to gain access to the world’s second largest market for pharmaceuticals.

China is striving for the world’s best, cheapest Healthcare


Leave a Reply

Your email address will not be published.